不借壳！荣耀来IPO了！投资方阵营豪华！

Group 1 - The article discusses the recent IPO counseling registrations of eight companies, including Tengli Transmission, Fangyi Co., and Huasheng Radar, indicating a trend of companies preparing for public offerings in China [1] - Tengli Transmission, which previously withdrew its IPO application in July 2024, is now seeking to re-enter the market with a focus on automotive components [3][4] - Fangyi Co. has recently completed a targeted financing of 60 million yuan and is preparing for an IPO on the Beijing Stock Exchange [7][8] - Huasheng Radar, a specialized radar technology company, has secured significant investment and has reported a doubling of orders in the first half of 2024 compared to its 2023 revenue [12][13] - Honor is positioning itself to become the third publicly listed smartphone giant in China, following Xiaomi and Transsion Holdings, with its IPO application submitted in June 2025 [14][15][16] - Lansheng Biotechnology, a low-toxicity pesticide manufacturer, has also initiated its IPO counseling, with a current valuation of 1.752 billion yuan [18][19][21] - Peiyuan Co., a hidden champion in the automotive shock absorber sector, is facing revenue growth without corresponding profit increases, indicating potential operational challenges [22] - Ziguang Zhanrui is preparing for an IPO on the Sci-Tech Innovation Board, aiming to become the first publicly listed domestic smartphone chip company, with a post-investment valuation of approximately 70 billion yuan [24][26] Group 2 - Tengli Transmission's revenue has shown consistent growth from 2020 to 2023, with total revenues of 2.92 billion yuan, 3.77 billion yuan, 5.10 billion yuan, and 6.1 billion yuan respectively, indicating a strong upward trend [5] - Fangyi Co. reported revenues of 1.93 billion yuan, 2.05 billion yuan, and 2.53 billion yuan from 2022 to 2024, but its net profit has seen a decline, highlighting profitability issues despite revenue growth [11] - Huasheng Radar's revenue for 2023 was 2.4 billion yuan, with a significant increase in orders in 2024, suggesting strong market demand for its products [13] - Lansheng Biotechnology's financial data shows a net profit of 2.69 billion yuan for 2024, with a focus on developing green pesticides and holding 39 patents [19][21] - Peiyuan Co. reported revenues of 6.34 billion yuan and 6.72 billion yuan for 2023 and 2024, respectively, but faced a decline in net profit, indicating operational challenges [22] - Ziguang Zhanrui's revenue figures for 2022, 2023, and 2024 were 14 billion yuan, 13 billion yuan, and 14.5 billion yuan, respectively, but the company has yet to achieve profitability [26]